Community or Nosocomial Urinary Tract Infections (UTI) are increasing worldwide speedily by creating problem to currently available β-lactam antibiotic therapies. Thus it is an urgent need of research to find the effective therapeutic options to treat / manage the UTI. Therefore, the present work is designed to determine prevalence of β-lactam resistance in seven novel bacterial isolates from the community UTI as well as to identify and characterize the types of β-lactamases involved in UTI. Total Five Hundred and Forty Nine (n= 549) clinical strains isolated from Urine samples and identified as E. coli, P. mirabilis, K. pneumoniae, P. aeruginosa, Enterobacter spp., Escherichia spp., Enterococcus spp., A. haemolyticus, Micrococcus, Serratia spp., Shigella spp., Staph. Aureus etc. Antimicrobial susceptibility profile of these strains revealed high level resistance to Ampicillin (99%), Ceftazidime (98.99%), Amoxicillin (98%), Cefotaxime (99%), Cefaclor (98%) and Penicillin (99%). Thus out of 549 only seven were detected as novel Extended Spectrum β-lactamase producers. All the seven isolates were identified at 16 S r RNA level and submitted to NCBI with following accession numbers such as: JX827388.1, JX827385, JX827384.1, JX827383.1, JX827382, JX827386 and JX827387. Minimum inhibitory concentration of each novel strain was determined against 25 different β-lactam antibiotics i.e. Ampicillin, Amoxiclav, Oxacillin, Vancomycin, Gentamycin, Ciprofloxacin, Nitrofurantoin, Ceftazidime, Cotrimaxazole, Trimethoprim, Imipenam, Amikacin, Amoxicillin, Cephalexin, Cefuroxime, Nalidixic acid, Cefazoline, Cefdinir, Cefexime, Ceftriaxone, Cefuroxime, Cefotaxime, Aztreonam, Cefaclor, Penicillin etc. All these strains revealed to possess virulence markers such as α-hemolysin, Cell surface hydrophobicity, Aerobactin production, Serum Resisitance, Colicine production etc. In addition to this an antimicrobial surveillance of the same strain was tested for multiple antibiotic resistance scale with the help of WHONET software designed by World Health Organization.
| Published in | Science Research (Volume 3, Issue 6) |
| DOI | 10.11648/j.sr.20150306.20 |
| Page(s) | 329-343 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2015. Published by Science Publishing Group |
β-lactamases, Urinary Tract Infection, WHONET Software, Virulance Markers
| [1] | C. Raju, S. Tiwari, “Urinary tract infection-A suitable approach”, Lecture notes. J. Ind. Acad. Clin. Med, Vol. 2, pp. 331-334, April 2004. |
| [2] | V. Gupta, A. Yadav, R. Joshi, “Antibiotic resistance patterns in Uropathogens”, Ind. J. Med. Microbiol, Vol. 20, pp.96-98, 2002. |
| [3] | H. Ogawara, “Antibiotic resistance in pathogenic bacteria, with special reference to β-lactam antibiotics”, Microbiol. Rev, Vol. 45, pp. 591-619, 1981. |
| [4] | P. Bradford, “Extended-spectrum β-lactamases in the 21st century: Characterization, Epidemiology, and detection of this important resistance threat”. Clin. Microbiol. Rev, Vol.14, pp. 933–951, 2001. |
| [5] | E. Sturnberg, D. Mack, “Extended spectrum β-lactamases: implications for the clinical microbiology laboratory, therapy and infection control,” J. Infction, Vol. 47, pp. 273-295, 2003. |
| [6] | M. Mishra, “Heamagglutination, Hemolysin production and Serum resistance of Proteus and related species isolated from clinical sources”, Ind. J. Med. Microbiol, Vol. 19 pp. 91, 2001. |
| [7] | L. Emody, M. Kerenyl, G. Nagy, “Virulence factors of uropathogenic Escherichia coli,” Int. J. Antimicrob. Agents, Vol. 22, pp. S22-S33, 2003. |
| [8] | National Committee for Clinical Laboratory Standards (NCCLS), “Performance standard for antimicrobial susceptibility testing, M100-S9. Pennsylvania, 2002. |
| [9] | R. Maskell, “Diagnosis of urinary tract infection, its causes and consequences. In: Urinary tract infection”, Curr. Top. Infect. Series. 3M Edward Arnold. London, pp. 21-41, 1982. |
| [10] | I. Porter, J. Bordie, “Boric acid preservation of urine samples”, Brit. Med. J, Vol. 2: 353-355, 1969. |
| [11] | W. Stamm, G. Counts, K. Running, “Diagnosis of coliforms infection in Acutely disuric Women,” New. Eng. J. Med, Vol. 307, pp. 463-468, 1982. |
| [12] | R. Stark, D. Maki, “Bacteriuria in the cauterized patient”, N. Engl. J. Med, Vol. 311, pp.560-564, 1984. |
| [13] | W. Martin, R. Brik, P. Yu, J. Washington II, “Identfication of members of family Enterobacteriaceae by the R-B system”, Appl. Microbiol, Vol. 20, pp. 880-883, 1970. |
| [14] | P. Smith, A. Morris, L. Relier, “Predicting urine culture results by dipstick testing and phase contrast microscopy”, Pathol, Vol. 35,pp. 161-165,February 2003. |
| [15] | M. Cheesbrough, “District laboratory practice in Tropical countries. Cambridge United Press, U.K., Vol. 27, pp. 105, 2000. |
| [16] | M. Cheesbrough, “In: Medical Laboratory Manual for Tropical Diseases. Vol II ESBLS. Tropical Health. Technology, pp60-69,198-205,147-8,154-5,415,537-43, 1985. |
| [17] | S. Khan, A. Ahmed, “Uropathogens and their susceptibility pattern: a restrospective analysis”, J. Pak. Med. Asso, Vol.51, pp.98-100, 2001. |
| [18] | A. Bauer, M. Kirby, C. Sherries, M. Turch, “Antibiotic susceptibility testing by a standard single Disc method,” Am. J. Clin. Pathol, Vol. 45, pp. 494-496, 1966. |
| [19] | D. Livermore, “β-lactamases in laboratory and clinical resistance,” Clin. Microbiol. Rev, Vol.8, pp.557-584, 1995. |
| [20] | Clinical Laboratory Standard Institute Performance standards for antimicrobial susceptibility testing. Twelfth informational supplement M100-S12.Wayne: CLSI; 2002. |
| [21] | B Behera1, P. Mathur, A. Das, A. Kapil, V. Sharma, “An evaluation of four different phenotypic techniques for detection of metallo-β-lactamase producing Pseudomonas aeruginosa”, Ind. J. Med.Microbiol.Vol.26,pp.233-237,March 2008. |
| [22] | P. Coudron, E. Moland, K. Thomson, “Occurrence and detection of AmpC β-lactamases among Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis isolates at a Veterans Medical Centre”, J. Clin. Microbiol, Vol. 38, pp. 1791–6, 2000. |
| [23] | R. Abbas, “Effect of Sub-inhibitory Concentrations of Gentamicin on the β-lactamase Production of Uropathogenic Escherichia Coli”, Res. J. Med. Sci, Vol.1,pp.63-67,2006. |
| [24] | G. Ross, K. Chanter, A. Harris, S. Kirby, “Comparison of assay techniques for β-lactamase activity,” Anal. Biochem, Vol. 54, pp. 9-16, 1973. |
| [25] | S. Maji, P. Dandapat, D. Ojha, C. Maity, S. Halder, P. Mohapatra, “ In vitro antimicrobial potentialities of different solvent extracts of ethanomedicinal plants against clinically isolated human pathogens,” J. Phytology, Vol. 2, pp.57-64,2010. |
| [26] | J. Sambrook, E. Fritsch, T. Maniatis, “Molecular cloning: a laboratory manual. New York: Cold Spring Harbor Laboratory, 1989. |
| [27] | M. Vidotto, E.Muller, J. Freitas,A. Alfieri, I. Guimaras, D. Santos, “Virulence factors of avian Escherchia coli,”.Avian. Dis, Vol. 34, pp. 531-538, 1990. |
| [28] | B. Brito, D. Leitte, “Virulence-associated factors of uropathogenic Escherichia coli strains isolated from pigs,” Vet. Microbiol, Vol. 65, pp. 123-132, 1999. |
| [29] | J. Blanco, M. Alonso, E. Gonzalez E, “Virulence factors of bacteriemic Escherichia coli with particular reference to production of cytotoxic necrotizing factor (CNF) by P-fimbriated strains”, J. Med. Microbiol, Vol.31.pp.175-183,1990. |
| [30] | K.Timmis, “Plasmid gene that specifies resistance to the bactericidal activity of serum, in Plasmids of medical, environmental and commercial importance”, edited by K N Timmis & Puhler (Elsevier, North Holland Biomedical Press, New York), 145-153, 1979. |
| [31] | J. Plorade, J. Sherris, K. Ryan, C. Georgeray, “Urinary tract infection. in: medical microbiology 1st ed . Elsevier New York * Amsterdam * Oxford ESBL,” Tropical Health Technology / Butterworth, Pp. 601-7, 247-8, 1984. |
| [32] | M. Manjula, D. Priya, G. Varsha, “Detection of extended spectrum β-lactamases producers among surgical wound infections and burn patients in JIMPMER”, Ind. J. Med .Microbiol, Vol.18, pp. 160-165, 2006. |
| [33] | R. Jones , K. Kugler, M. Pfaller, P. Winokur, “Characteristics of pathogens causing Urinary tract infections in hospitals in North America. Results from the SENTRY antimicrobial Surveillance Program1997,”Diagn. Microbiol. Infect. Dis, Vol. 33, pp. 55-63, 1999. |
| [34] | G. Kahlmeter, “An international survey of the antimicrobial susceptibility of pathogens from uncomplicated Urinary tract infections: the ECO.SENS Project,” J. Antimicrob. Chemother, Vol. 51, pp. 69-76, 2003. |
| [35] | C. Brun-Buisson, P. Legrand, A. Phillippon, F. Montravers, M. Ansquer , J. Duval J, “Transferable enzymatic resistant to third generation cephalosporin during nosocomial out breaks of multi resistant Klebsiella pneumonia,” Lancet. Vol. 2, pp.302-306, 1987. |
| [36] | V. Jarlier, M. Nicolas, G. Fournier, “Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns,” Rev. Infect. Dis, Vol.10, pp.867–78., 1988. |
| [37] | B. Navneeth, D. Sridaran, D. Sahay, M. Belwadi, “A preliminary study of metallo-β-lactamase producing Pseudomonas aeruginosa in hospitalized patients,” Ind. J. Med. Res, Vol. 116, pp.264-268, 2002. |
| [38] | V. Gupta, P. Datta, J. Chander, “Prevalence of metallo-β-lactamase (MBL) producing Pseudomonas spp and Acinetobacter spp in a tertiary care hospital in India,” J. Inf, Vol. 52, pp.311-4, 2006. |
| [39] | M. Jesudason, A. Kandathil, V. Balaji, “Comparison of two methods to detect carbapenemase and metallo-β- lactamase production in clinical isolates,” Ind. J .Med. Res, Vol. 121, pp. 780-3, 2005. |
| [40] | J. Yan, J. Wu, S. Tsai, C. Chuang, “Comparison of the double disk, combined-disk, and E Test methods for detecting metallo- β-lactamases in gram-negative bacilli”, Diagn. Microbiol. Inf. Dis, Vol.49, pp. 5-11, 2004. |
| [41] | H. Smith, “The haemolysins of Escherichia coli,” J. Pathol. Bacteriol, Vol. 85, pp. 197-211, 1963. |
| [42] | J. Johnson, “Virulence factors in Escherichia coli urinary tract infection,” Clin. Microbiol. Rev, Vol.4, pp. 81-128, 1991. |
| [43] | J. Blanco, M. Alonso, E. Gonzalez E, “Virulence factors of bacteriemic Escherichia coli with particular reference to production of cytotoxic necrotizing factor (CNF) by P-fimbriated strains,” J. Med. Microbiol, Vol.31pp.175-183, 1990. |
| [44] | S. Mudd, E. Mudd, “The penetration of bacteria through capillary spaces IV. A kinetic mechanism in interfaces,” J. Exp. Med, Vol.40, pp. 633-45, 1924. |
| [45] | B. Sleytr, P. Messner, “Crystalline surface layers of bacteria,” Ann. Rev. Microbiol, Vol. 37, pp. 311- 339, 1983. |
| [46] | I. Sheldon, D. Noakes, A. Rycroft, “Effect of postpartum manual examination of the vagina on uterine bacterial contamination in cows,” Vet. Rec, Vol. 151, pp.531-534, 2002. |
| [47] | P. Taylor, “Bactericidal and bacteriolytic activity of serum against gram negative bacteria,”Microbiol. Rev, Vol.47, pp. 46-83, 1983. |
| [48] | M. Montenegro, D. Bittersuermann, J. Jimmis, “Serum resistance and pathogenicity related factors in clinical isolates of Escherichia coli and other gram negative bacteria,” J. Gen. Microbiol, Vol.131, pp. 1511-21. |
| [49] | W. Stamm, “Scientific and clinical challenges in the management of urinary tract infections,” Am. J. Med, Vol.113, pp. 1S-4S, 2002. |
APA Style
Rashmi M. Bhande – Kolhapure. (2015). Incidence of β-lactamases Among Novel Multidrug Resistant Clinical Isolates of UTI Patients: An Antimicrobial Resistance Surveillance Study. Science Research, 3(6), 329-343. https://doi.org/10.11648/j.sr.20150306.20
ACS Style
Rashmi M. Bhande – Kolhapure. Incidence of β-lactamases Among Novel Multidrug Resistant Clinical Isolates of UTI Patients: An Antimicrobial Resistance Surveillance Study. Sci. Res. 2015, 3(6), 329-343. doi: 10.11648/j.sr.20150306.20
AMA Style
Rashmi M. Bhande – Kolhapure. Incidence of β-lactamases Among Novel Multidrug Resistant Clinical Isolates of UTI Patients: An Antimicrobial Resistance Surveillance Study. Sci Res. 2015;3(6):329-343. doi: 10.11648/j.sr.20150306.20
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.sr.20150306.20,
author = {Rashmi M. Bhande – Kolhapure},
title = {Incidence of β-lactamases Among Novel Multidrug Resistant Clinical Isolates of UTI Patients: An Antimicrobial Resistance Surveillance Study},
journal = {Science Research},
volume = {3},
number = {6},
pages = {329-343},
doi = {10.11648/j.sr.20150306.20},
url = {https://doi.org/10.11648/j.sr.20150306.20},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sr.20150306.20},
abstract = {Community or Nosocomial Urinary Tract Infections (UTI) are increasing worldwide speedily by creating problem to currently available β-lactam antibiotic therapies. Thus it is an urgent need of research to find the effective therapeutic options to treat / manage the UTI. Therefore, the present work is designed to determine prevalence of β-lactam resistance in seven novel bacterial isolates from the community UTI as well as to identify and characterize the types of β-lactamases involved in UTI. Total Five Hundred and Forty Nine (n= 549) clinical strains isolated from Urine samples and identified as E. coli, P. mirabilis, K. pneumoniae, P. aeruginosa, Enterobacter spp., Escherichia spp., Enterococcus spp., A. haemolyticus, Micrococcus, Serratia spp., Shigella spp., Staph. Aureus etc. Antimicrobial susceptibility profile of these strains revealed high level resistance to Ampicillin (99%), Ceftazidime (98.99%), Amoxicillin (98%), Cefotaxime (99%), Cefaclor (98%) and Penicillin (99%). Thus out of 549 only seven were detected as novel Extended Spectrum β-lactamase producers. All the seven isolates were identified at 16 S r RNA level and submitted to NCBI with following accession numbers such as: JX827388.1, JX827385, JX827384.1, JX827383.1, JX827382, JX827386 and JX827387. Minimum inhibitory concentration of each novel strain was determined against 25 different β-lactam antibiotics i.e. Ampicillin, Amoxiclav, Oxacillin, Vancomycin, Gentamycin, Ciprofloxacin, Nitrofurantoin, Ceftazidime, Cotrimaxazole, Trimethoprim, Imipenam, Amikacin, Amoxicillin, Cephalexin, Cefuroxime, Nalidixic acid, Cefazoline, Cefdinir, Cefexime, Ceftriaxone, Cefuroxime, Cefotaxime, Aztreonam, Cefaclor, Penicillin etc. All these strains revealed to possess virulence markers such as α-hemolysin, Cell surface hydrophobicity, Aerobactin production, Serum Resisitance, Colicine production etc. In addition to this an antimicrobial surveillance of the same strain was tested for multiple antibiotic resistance scale with the help of WHONET software designed by World Health Organization.},
year = {2015}
}
TY - JOUR T1 - Incidence of β-lactamases Among Novel Multidrug Resistant Clinical Isolates of UTI Patients: An Antimicrobial Resistance Surveillance Study AU - Rashmi M. Bhande – Kolhapure Y1 - 2015/12/18 PY - 2015 N1 - https://doi.org/10.11648/j.sr.20150306.20 DO - 10.11648/j.sr.20150306.20 T2 - Science Research JF - Science Research JO - Science Research SP - 329 EP - 343 PB - Science Publishing Group SN - 2329-0927 UR - https://doi.org/10.11648/j.sr.20150306.20 AB - Community or Nosocomial Urinary Tract Infections (UTI) are increasing worldwide speedily by creating problem to currently available β-lactam antibiotic therapies. Thus it is an urgent need of research to find the effective therapeutic options to treat / manage the UTI. Therefore, the present work is designed to determine prevalence of β-lactam resistance in seven novel bacterial isolates from the community UTI as well as to identify and characterize the types of β-lactamases involved in UTI. Total Five Hundred and Forty Nine (n= 549) clinical strains isolated from Urine samples and identified as E. coli, P. mirabilis, K. pneumoniae, P. aeruginosa, Enterobacter spp., Escherichia spp., Enterococcus spp., A. haemolyticus, Micrococcus, Serratia spp., Shigella spp., Staph. Aureus etc. Antimicrobial susceptibility profile of these strains revealed high level resistance to Ampicillin (99%), Ceftazidime (98.99%), Amoxicillin (98%), Cefotaxime (99%), Cefaclor (98%) and Penicillin (99%). Thus out of 549 only seven were detected as novel Extended Spectrum β-lactamase producers. All the seven isolates were identified at 16 S r RNA level and submitted to NCBI with following accession numbers such as: JX827388.1, JX827385, JX827384.1, JX827383.1, JX827382, JX827386 and JX827387. Minimum inhibitory concentration of each novel strain was determined against 25 different β-lactam antibiotics i.e. Ampicillin, Amoxiclav, Oxacillin, Vancomycin, Gentamycin, Ciprofloxacin, Nitrofurantoin, Ceftazidime, Cotrimaxazole, Trimethoprim, Imipenam, Amikacin, Amoxicillin, Cephalexin, Cefuroxime, Nalidixic acid, Cefazoline, Cefdinir, Cefexime, Ceftriaxone, Cefuroxime, Cefotaxime, Aztreonam, Cefaclor, Penicillin etc. All these strains revealed to possess virulence markers such as α-hemolysin, Cell surface hydrophobicity, Aerobactin production, Serum Resisitance, Colicine production etc. In addition to this an antimicrobial surveillance of the same strain was tested for multiple antibiotic resistance scale with the help of WHONET software designed by World Health Organization. VL - 3 IS - 6 ER -
Information
Email: